Recombinant human IL‑18 is a pro‑inflammatory cytokine that enhances natural killer (NK) cell activation, proliferation, and IFN‑γ production, reflecting its natural role in stimulating NK and T‑cell responses. Human IL-18 is optimized for use in cell culture and functional assays.
Recombinant human IL‑18 is a pro‑inflammatory cytokine that enhances natural killer (NK) cell activation, proliferation, and IFN‑γ production, reflecting its natural role in stimulating NK and T‑cell responses. Human IL-18 is optimized for use in cell culture and functional assays.
Human IL-18 can be used for a variety of applications including:
- In vitro expansion and activation of NK cells.
- Generation of cytokine-induced memory-like NK cells (CIML NK).
- Enhancing T cell activation and effector functions in CAR-T cell applications.
- Investigation of IL-18 mediated signaling pathways.
Optimal concentration for a specific application should be determined by a dose-response experiment.
Biological activity
Human Interleukin 18 (IL-18) is a pro inflammatory cytokine of the IL-1 family that plays a central role in both innate and adaptive immunity. IL-18 is produced by a broad range of cell types, including monocytes, macrophages, keratinocytes, mesenchymal cells, and epithelial cells.
IL-18 is synthesized as an inactive precursor that lacks a signal peptide and therefore accumulates in the cytosol. It requires caspase 1–mediated proteolytic cleavage for activation. Active caspase 1 simultaneously cleaves gasdermin D, liberating a pore-forming domain that enables secretion of the mature protein.
IL-18 exerts strong immunostimulatory effects, most notably by inducing IFN-γ production in T cells, natural killer (NK) cells, and NKT cells. Recombinant IL-18 is used in vitro to activate and enhance the effector functions of NK cells, including IFN-γ production and cytotoxicity. In synergy with cytokines such as IL-2, IL-12, IL-15, and IL-21, it promotes NK cell activation, proliferation, and inflammatory cytokine release. IL-18 can be used in combination with IL-12 and IL-15 to generate cytokine induced memory like (CIML) NK cells with increased longevity and anti cancer functionality. Exposure to IL-18 has also been shown to enhance the anti-cancer functions of CAR T cells.
IL-18 also stimulates additional immune cell types, including macrophages, B cells, and dendritic cells. The recombinant protein corresponds to the mature, bioactive form of IL-18 generated after caspase 1 cleavage.
Research-grade cytokines are suitable for a wide variety of cell culture applications. They are sterile-filtered prior to lyophilization. Generally, endotoxin levels are <0.1 ng/μg (<1 EU/μg), and purities are >95%. The biological activity is tested in appropriate bioassays.
Premium-grade cytokines offer the convenience of high and well-defined biological activities and allow exact unit dosing for demanding applications. The biological activity is determined after lyophilization and reconstitution, and normalized to WHO/NIBSC standards whenever available. In general, endotoxin levels are <0.01 ng/μg (<0.1 EU/μg), and purities are >97%. Lot-specific activities are stated in the Certificate of Analysis (www. miltenyibiotec.com/certificates).
SDS-PAGE of Human IL-18 under reducing (R) and non-reducing (NR) conditions.
Human IL-18 activity assay. The biological activity of Human IL-18, premium grade was determined by induction of IFN-γ secretion by KG-1 cells.
Mass spectrometry analysis (ESI-MS) of Human IL-18, premium grade. The peak corresponds to the calculated molecular mass of 18152 Da.
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Konishi, K. et al. (1997) A simple and sensitive bioassay for the detection of human interleukin-18/interferon-gamma-inducing factor using human myelomonocytic KG-1 cells. J Immunol Methods 209 (2): 187-191
You have previously chosen International as your location.
What do you want to do?